Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Go back to Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 0.69 +0.04 (6.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $0.03 | |||
| Open | $0.69 | 52 Week Low | $0.01 | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.65 | EPS | $0.00 | |||
| Volume | 2,818,656 | |||||
